MedTrace Logo

A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer

NCT01517009 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-06-26

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility of chemotherapy, consisting of docetaxel, cisplatin and capecitabine given prior to surgery for stomach cancer. Furthermore, an extended type of removal of lymph nodes will be implemented.

Conditions

Interventions

DRUG

Docetaxel

60 mg/m2, 1 gift every 3 weeks, in total 4 gifts

DRUG

cisplatin

60 mg/m2, one gift every three weeks, in total 4 gift

DRUG

Capecitabine

1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles

PROCEDURE

D1extra-resection

An extended lymphadenectomy compared to a D1 resection for gastric cancer

Sponsors & Collaborators

  • Eindhoven Cancer Registry

    collaborator OTHER

  • Jeroen Bosch Ziekenhuis

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-11-30
Completion
2013-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01517009 on ClinicalTrials.gov